Gene Bridges Licenses Recombineering Technology to Chugai Pharmaceutical Co., Ltd.
Gene Bridges GmbH announced that Chugai Pharmaceutical Co., Ltd. of Tokyo, Japan has completed the amendment to expand the commercial license agreement existing since 2005 for the use of the Red/ET recombination technology from Gene Bridges. The Red/ET recombination technology, patented in Japan under the title "Novel DNA cloning Method“, is a method for generating targeting vectors or modifying E. coli chromosomes.
“Red/ET is fast becoming the standard DNA engineering technology used in industry and academia worldwide,” commented Gary Stevens, CEO of Gene Bridges GmbH. “Having recently also licensed Red/ET to Daiichi Sankyo and Takeda we are delighted to be signing this amendment to another leading Japanese Pharmaceutical company, which found the existing license agreement worthwhile expanding.”
Gene Bridges is represented in Japan by the distribution partner Funakoshi.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.